Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study evaluating the efficacy of Lenalidomide in association with Rituximab in refractory or relapse of primary central nervous system lymphoma (PCNSL)

Trial Profile

Phase II study evaluating the efficacy of Lenalidomide in association with Rituximab in refractory or relapse of primary central nervous system lymphoma (PCNSL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Dexamethasone
  • Indications CNS cancer; Diffuse large B cell lymphoma; Lymphoma
  • Focus Proof of concept; Therapeutic Use
  • Acronyms REVRI
  • Most Recent Events

    • 09 Jul 2019 Status changed from active, no longer recruiting to completed.
    • 04 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Apr 2019.
    • 29 Jan 2019 Results published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top